In a filing, Verrica Pharmaceuticals Inc. revealed its Director Manning Paul B acquired Company’s shares for reported $1.0 million on Jul 24. In the deal valued at $5.02 per share,200,000 shares were bought. As a result of this transaction, Manning Paul B now holds 7,851,128 shares worth roughly $ 36.35 million.
Then, White Ted sold 50,677 shares, generating $244,770 in total proceeds. Upon selling the shares at $4.83, the President and CEO now owns 128,789 shares.
Before that, Bonaccorso Joe sold 38,262 shares. Verrica Pharmaceuticals Inc. shares valued at $184,805 were divested by the Chief Commercial Officer at a price of $4.83 per share. As a result of the transaction, Bonaccorso Joe now holds 62,738 shares, worth roughly $0.29 million.
Needham upgraded its Verrica Pharmaceuticals Inc. [VRCA] rating to a Buy from a a Hold in a research note published on Friday. PT values the company’s stock at a premium of 53.7 to its Friday closing price.
Price Performance Review of VRCA
On Friday, Verrica Pharmaceuticals Inc. [NASDAQ:VRCA] saw its stock jump 1.76% to $4.63. On the same session, the stock had its day’s lowest price of $4.55, but rose to a high of $4.81. Over the last five days, the stock has gained 3.12%. Verrica Pharmaceuticals Inc. shares have risen nearly 68.36% since the year began. Nevertheless, the stocks have risen 18.11% over the past one year. While a 52-week high of $8.69 was reached on 02/23/23, a 52-week low of $2.02 was recorded on 01/03/23. SMA at 50 days reached $5.55, while 200 days put it at $5.42. A total of 0.26 million shares were traded, compared to the trading of 0.22 million shares in the previous session.
Levels Of Support And Resistance For VRCA Stock
The 24-hour chart illustrates a support level at 4.52, which if violated will result in even more drops to 4.40. On the upside, there is a resistance level at 4.78. A further resistance level may holdings at 4.92. The Relative Strength Index (RSI) on the 14-day chart is 40.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 55.06%. Stochastics %K at 33.15% indicates the stock is a holding.
How much short interest is there in Verrica Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Verrica Pharmaceuticals Inc. stocks on Aug 14, 2023, growing by 1.49 million shares to a total of 4.51 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 3.02 million shares. There was a rise of 33.04%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 21.64% of the overall stock float, the days-to-cover ratio (short ratio) rose to 6.81.
Verrica Pharmaceuticals Inc. [VRCA] – Who Are The Largest Shareholders?
In filings from Perceptive Advisors LLC, it is revealed that the company now owns 5,038,983 shares, or roughly 12.01% of the outstanding VRCA shares. Additionally, Avoro Capital Advisor LLC increased 11.47% of its stake after which the total value it holdings stand at $17,251,734, while The Vanguard Group, Inc. added 6.60% of its stake to hold $6.91 million in the firm. Over the last quarter, Fidelity Management & Research Co sold -197,813 shares of Verrica Pharmaceuticals Inc., while BlackRock Fund Advisors sold 804,441 shares. At present, Geode Capital Management LLC is holding 388,507 shares valued at $2.27 million. SSgA Funds Management, Inc. owned 376,111 shares of the company at the time of its most recent 13F filing, worth $2.2 million.
According to FactSet, Verrica Pharmaceuticals Inc.’s share price will average $12.67 in the next year, based on opinions of analysts polled by the firm. This is up nearly 185.71 percent from its previous closing price of $4.55. Analysts expect Verrica Pharmaceuticals Inc. stock to reach the higher price of $15.00, while the lowest price estimate is $10.00. However, 6 analysts have rated VRCA stock as a Buy in their predictions for 2023.